Treatment of giant cell arteritis.

Curr Opin Ophthalmol

aDepartment of Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital bBaylor College of Medicine cDepartment of Ophthalmology, Neurology and Neurosurgery, Weill Cornell Medical College dUTMB Galveston eUT M.D. Anderson Cancer Center, Houston, Texas fThe University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.

Published: November 2015

Purpose Of Review: Giant cell arteritis (GCA) remains a potentially blinding inflammatory vasculitis of the elderly. Because prolonged doses of corticosteroids remain the best established treatment, side-effects during treatment are common and potentially serious. This review addresses the challenges clinicians face in managing this disease.

Recent Findings: High-dose corticosteroids with slow tapering and close monitoring are the mainstay of treatment. Investigations into adjunctive treatment have yet to establish other agents as beneficial, but further research is ongoing with some promising results.

Summary: GCA represents a challenging illness to clinicians because of its potential for causing blindness and the need for prolonged high doses of corticosteroids with their many complications.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICU.0000000000000201DOI Listing

Publication Analysis

Top Keywords

giant cell
8
cell arteritis
8
doses corticosteroids
8
treatment
5
treatment giant
4
arteritis purpose
4
purpose review
4
review giant
4
arteritis gca
4
gca remains
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!